Label: BROMFED DM- brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide syrup 

  • Label RSS
  • NDC Code(s): 60432-837-04, 60432-837-15, 60432-837-16
  • Packager: Morton Grove Pharmaceuticals, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated 01/14

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Rx only

    Close
  • DESCRIPTION

    Bromfed® DM Cough Syrup is a clear, light pink syrup with a butterscotch flavor.

    Each 5 mL (1 teaspoonful) contains:

    Brompheniramine Maleate, USP     . . . . . . . .  2 mg

    Pseudoephedrine Hydrochloride, USP . . . . . 30 mg

    Dextromethorphan Hydrobromide, USP  . . . 10 mg

    Alcohol 0.95% v/v

    In a palatable, aromatic vehicle.

    Inactive Ingredients: artificial butterscotch flavor, citric acid anhydrous, dehydrated alcohol, FD&C Red No. 40, glycerin, liquid sugar, methylparaben, propylene glycol, purified water and sodium benzoate. It may contain 10% citric acid solution or 10% sodium citrate solution for pH adjustment. The pH range is between 3.0 and 6.0.

    Chemical Structure

    C16H19BrN2•C4H4O4          M.W. 435.31

    Brompheniramine Maleate, USP
    (±)-2- p-Bromo-α-2-(dimethylamino)ethylbenzylpyridine maleate (1:1)
    Chemical Structure

    C10H15NO•HCl                    M.W. 201.69

    Pseudoephedrine Hydrochloride, USP
    (+)-Pseudoephedrine hydrochloride
    Chemical Structure

    C18H25NO•HBr•H2O          M.W. 370.32

    Dextromethorphan Hydrobromide, USP
    3-Methoxy-17-methyl-9α, 13α, 14α -morphinan hydrobromide monohydrate

    Antihistamine/Nasal Decongestant/Antitussive syrup for oral administration.

    Close
  • CLINICAL PHARMACOLOGY

    Brompheniramine maleate is a histamine antagonist, specifically an H1-receptor-blocking agent belonging to the alkylamine class of antihistamines. Antihistamines appear to compete with histamine for receptor sites on effector cells. Brompheniramine also has anticholinergic (drying) and sedative effects. Among the antihistaminic effects, it antagonizes the allergic response (vasodilation, increased vascular permeability, increased mucus secretion) of nasal tissue. Brompheniramine is well absorbed from the gastrointestinal tract, with peak plasma concentration after single, oral dose of 4 mg reached in 5 hours; urinary excretion is the major route of elimination, mostly as products of biodegradation; the liver is assumed to be the main site of metabolic transformation.

    Pseudoephedrine acts on sympathetic nerve endings and also on smooth muscle, making it useful as a nasal decongestant. The nasal decongestant effect is mediated by the action of pseudoephedrine on α-sympathetic receptors, producing vasoconstriction of the dilated nasal arterioles. Following oral administration, effects are noted within 30 minutes with peak activity occurring at approximately one hour.

    Dextromethorphan acts centrally to elevate the threshold for coughing. It has no analgesic or addictive properties. The onset of antitussive action occurs in 15 to 30 minutes after administration and is of long duration.

    Close
  • INDICATIONS AND USAGE

    For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.

    Close
  • CONTRAINDICATIONS

    Hypersensitivity to any of the ingredients. Do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. Do not use dextromethorphan in patients receiving monoamine oxidase (MAOI) inhibitors (see Drug Interactions).

    Antihistamines should not be used to treat lower respiratory tract conditions including asthma.

    Close
  • WARNINGS

    Especially in infants and small children, antihistamines in overdosage may cause hallucinations, convulsions, and death.

    Antihistamines may diminish mental alertness. In the young child, they may produce excitation.

    Close
  • PRECAUTIONS

    General

    Because of its antihistamine component, Bromfed® DM Cough Syrup should be used with caution in patients with a history of bronchial asthma, narrow angle glaucoma, gastrointestinal obstruction, or urinary bladder neck obstruction. Because of its sympathomimetic component, Bromfed® DM Cough Syrup should be used with caution in patients with diabetes, hypertension, heart disease, or thyroid disease.

    Information for Patients

    Patients should be warned about engaging in activities requiring mental alertness, such as driving a car or operating dangerous machinery.

    Drug Interactions

    Monoamine oxidase (MAO) inhibitors

    Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Bromfed® DM Cough Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS).

    Central nervous system (CNS) depressants

    Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.).

    Antihypertensive drugs

    Sympathomimetic may reduce the effects of antihypertensive drugs.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    Animal studies of Bromfed® DM Cough Syrup to assess the carcinogenic and mutagenic potential or the effect on fertility have not been performed.

    Pregnancy

    Teratogenic Effects

    Pregnancy Category C

    Animal reproduction studies have not been conducted with Bromfed® DM Cough Syrup. It is also not known whether Bromfed® DM Cough Syrup can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. It should be given to a pregnant woman only if clearly needed.

    Reproduction studies of brompheniramine maleate (a component of Bromfed® DM Cough Syrup) in rats and mice at doses up to 16 times the maximum human doses have revealed no evidence of impaired fertility or harm to the fetus.

    Nursing Mothers

    Because of the higher risk of intolerance of antihistamines in small infants generally, and in newborns and prematures in particular, Bromfed® DM Cough Syrup is contraindicated in nursing mothers.

    Pediatric Use

    Safety and effectiveness in pediatric patients below the age of 6 months have not been established (see DOSAGE AND ADMINISTRATION).

    Close
  • ADVERSE REACTIONS

    The most frequent adverse reactions to Bromfed® DM Cough Syrup are: sedation; dryness of mouth, nose and throat; thickening of bronchial secretions; dizziness. Other adverse reactions may include:

    Dermatologic: Urticaria, drug rash, photosensitivity, pruritus.

    Cardiovascular System: Hypotension, hypertension, cardiac arrhythmias, palpitation.

    CNS: Disturbed coordination, tremor, irritability, insomnia, visual disturbances, weakness, nervousness, convulsions, headache, euphoria, and dysphoria.

    G.U. System: Urinary frequency, difficult urination.

    G.I. System: Epigastric discomfort, anorexia, nausea, vomiting, diarrhea, constipation.

    Respiratory System: Tightness of chest and wheezing, shortness of breath.

    Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis.

    Close
  • OVERDOSAGE

    Signs and Symptoms

    Central nervous system effects from overdosage of brompheniramine may vary from depression to stimulation, especially in children. Anticholinergic effects may be noted. Toxic doses of pseudoephedrine may result in CNS stimulation, tachycardia, hypertension, and cardiac arrhythmias; signs of CNS depression may occasionally be seen. Dextromethorphan in toxic doses will cause drowsiness, ataxia, nystagmus, opisthotonos, and convulsive seizures.

    Toxic Doses

    Data suggest that individuals may respond in an unexpected manner to apparently small amounts of a particular drug. A 2½-year-old child survived the ingestion of 21 mg/kg of dextromethorphan exhibiting only ataxia, drowsiness, and fever, but seizures have been reported in 2 children following the ingestion of 13–17 mg/kg. Another 2½-year-old child survived a dose of 300–900 mg of brompheniramine. The toxic dose of pseudoephedrine should be less than that of ephedrine, which is estimated to be 50 mg/kg.

    Treatment

    Induce emesis if patient is alert and is seen prior to 6 hours following ingestion. Precautions against aspiration must be taken, especially in infants and small children. Gastric lavage may be carried out, although in some instances tracheostomy may be necessary prior to lavage. Naloxone hydrochloride 0.005 mg/kg intravenously may be of value in reversing the CNS depression that may occur from an overdose of dextromethorphan. CNS stimulants may counter CNS depression. Should CNS hyperactivity or convulsive seizures occur, intravenous short-acting barbiturates may be indicated. Hypertensive responses and/or tachycardia should be treated appropriately. Oxygen, intravenous fluids, and other supportive measures should be employed as indicated.

    Close
  • DOSAGE AND ADMINISTRATION

    Adults and pediatric patients 12 years of age and over: 10 mL (2 teaspoonfuls) every 4 hours. Children 6 to under 12 years of age: 5 mL (1 teaspoonful) every 4 hours. Children 2 to under 6 years of age: 2.5 mL (½ teaspoonful) every 4 hours. Infants 6 months to under 2 years of age: Dosage to be established by a physician.

    Do not exceed 6 doses during a 24-hour period.

    Close
  • HOW SUPPLIED

    Bromfed® DM Cough Syrup is a clear, light pink-colored, butterscotch-flavored syrup containing in each 5 mL (1 teaspoonful) brompheniramine maleate 2 mg, pseudoephedrine hydrochloride 30 mg and dextromethorphan hydrobromide 10 mg, available in the following sizes:

    15 mL (Professional Sample-Not For Resale)
    4 fl oz (118 mL)
    1 Pint (473 mL)

    RECOMMENDED STORAGE

    Store at 20 ° to 25 °C (68 ° to 77 °F) [See USP Controlled Room Temperature].

    KEEP TIGHTLY CLOSED

    Dispense in a tight, light-resistant container as defined in the USP.

    Close
  • SPL UNCLASSIFIED SECTION

    Rx Only

    Product No.: 8837

    BROMFED® is a registered trademark of Wockhardt.

    Logo

    Manufactured For:
    Wockhardt USA, LLC
    Parsippany, NJ 07054

    Manufactured By:
    Morton Grove Pharmaceuticals, Inc.
    Morton Grove, IL 60053

    A50-8837-16
    REV. 02-10

    Close
  • PRINCIPAL DISPLAY PANEL - 118 mL Bottle Label

    NDC 60432-837-04

    FDA-Approved
    Bromfed® DM
    Cough Syrup

    Each 5 mL (teaspoonful) contains:
    Brompheniramine Maleate, USP  2 mg
    Pseudoephedrine Hydrochloride, USP  30 mg
    Dextromethorphan Hydrobromide, USP  10 mg

    Alcohol 0.95% v/v

    Rx Only

    WOCKHARDT
    NET: 4 fl oz (118 mL)

    DO NOT USE IF INNER FOIL SEAL PRINTED "SEALED
    FOR YOUR PROTECTION" IS BROKEN OR MISSING.

    PRINCIPAL DISPLAY PANEL - 118 mL Bottle Label
    Close
  • INGREDIENTS AND APPEARANCE
    BROMFED  DM
    brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide syrup
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:60432-837
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Brompheniramine Maleate (Brompheniramine) Brompheniramine Maleate 2 mg  in 5 mL
    Pseudoephedrine Hydrochloride (Pseudoephedrine) Pseudoephedrine Hydrochloride 30 mg  in 5 mL
    Dextromethorphan Hydrobromide (Dextromethorphan) Dextromethorphan Hydrobromide 10 mg  in 5 mL
    Inactive Ingredients
    Ingredient Name Strength
    Water  
    Glycerin  
    Propylene Glycol  
    Sodium Benzoate  
    Anhydrous Citric Acid  
    Alcohol  
    Methylparaben  
    FD&C Red No. 40  
    Product Characteristics
    Color PINK (Light Pink) Score     
    Shape Size
    Flavor BUTTERSCOTCH Imprint Code
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:60432-837-15 15 mL in 1 BOTTLE, PLASTIC
    2 NDC:60432-837-04 118 mL in 1 BOTTLE, PLASTIC
    3 NDC:60432-837-16 473 mL in 1 BOTTLE, PLASTIC
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA088811 06/15/2010
    Labeler - Morton Grove Pharmaceuticals, Inc. (801897505)
    Close